Last $36.65 USD
Change Today +0.15 / 0.41%
Volume 285.9K
MYGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

topathologist in the diagnosis of melanoma. myPath Melanoma might provide a tool to assist physicians in correctly diagnosing indeterminate skin lesions. myPath Melanoma was released through an early access launch, which began in November 2013. myPlan Lung Cancer: A prognostic medicine test for lung cancer. The company’s myPlan Lung Cancer test is a gene expression based profile that might aid a physician in making a determination as to the aggressiveness of a patient’s lung cancer and based upon this determination guide patient therapy. This test might be clinically applicable in the approximately 30,000 new lung cancer diagnoses every year that are early stage lung cancer. myPlan Lung Cancer was released through an early access launch, which began in October 2013. myRisk Hereditary Cancer: A predictive medicine test for hereditary cancer. The company’s myRisk Hereditary Cancer test represents the next generation of its existing hereditary cancer franchisem, which the company anticipates would eventually replace its predictive medicine test offerings (BRACAnalysis, Colaris, Colaris AP, Melaris, and Panexia) with a single test. myRisk Hereditary Cancer is designed to determine a patient’s hereditary cancer risk for breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer, and gastric cancer. myRisk Hereditary Cancer was initially released through an early access launch, which began in September 2013. PANEXIA: A predictive medicine test for pancreatic cancer. The company’s PANEXIA test is an analysis of the PALB2 and BRCA2 genes for assessing a person’s risk of developing pancreatic cancer later in life. Individuals with a mutation detected by the PANEXIA test have approximately an 8.6-fold higher risk than the general population of developing pancreatic cancer. If an individual with a family history of pancreatic cancer receives the PANEXIA test and is identified as having a deleterious mutation, increased surveillance and other predictive steps could be taken in an effort to detect the cancer at an early stage where it might be treatable. PREZEON: A personalized medicine test for cancer. The company’s PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in cancerous tumors. The PTEN gene is one of the important tumor suppressor genes and its loss of function is associated with more aggressive disease progression and poorer survival. The PTEN gene plays a role in the disease progression of all four of the major cancers, such as breast, prostate, colon, and lung cancer. The PTEN gene also plays a critical role in cell signaling pathways that are the target of various cancer drugs, such as EGFR, mTOR, and PIK3CA inhibitors. Analysis of PTEN function might help oncologists in identifying patients who would likely respond to these classes of cancer drugs. Prolaris: A prognostic medicine test for prostate cancer. The company’s Prolaris test is a gene expression assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that could be monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. VectraDA: A personalized medicine test for rheumatoid arthritis (RA). The company’s Vectra DA test is an objective multi-biomaker blood test validated to measure RA disease activity. Vectra DA assesses multiple mechanisms and pathways associated with RA disease activity and integrates the concentrations of 12 serum proteins into a single score reported on a scale of 1 to 100. The test might be used throughout the course of a patient’s disease and provides clinicians with expanded insight on disease severity, risk of radiographic progression, response to therapy and the effect of comorbidities. Pharmaceutical and Clinical Services As of June 30, 2014, Rules-Based Medicine, Inc. was operating as a wholly-owned subsidiary of the company under the name of Myriad RBM, Inc. (Myriad RBM). The acquisition expanded the company’s test pipeline into new disease st

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $36.65 USD +0.15

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $23.21 USD +0.21
Bio-Reference Laboratories Inc $31.73 USD -0.09
Foundation Medicine Inc $23.96 USD -0.03
Genomic Health Inc $32.50 USD +0.06
Imperial Innovations Group PLC 497.50 GBp -2.50
View Industry Companies
 

Industry Analysis

MYGN

Industry Average

Valuation MYGN Industry Range
Price/Earnings 20.6x
Price/Sales 3.6x
Price/Book 3.8x
Price/Cash Flow 19.6x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.